#Canada #Innovation #Duchesnay #Blainville #pharmaceuticals

Duchesnay Pharmaceutical Group Expands Production Capacity

Duchesnay Pharmaceutical Group (DPG), a recognized leader in the pharmaceutical sector, is making significant strides in its growth strategy with the recent implementation of a second shift in its production operations. This development comes as a direct response to the increasing global demand for its flagship products, and it marks an important advancement in the company’s commitment to improving patient access to essential medications.

A Strategic Milestone for Global Expansion

On September 16, 2025, the company proudly announced this initiative, which aims to bolster its production capacity by an impressive 50% within the next two years. Such a move not only reinforces DPG's position in the competitive healthcare landscape but also enhances its ability to serve patients in more than 40 countries where its products are already approved.

As Éric Gervais, President of DPG, stated, “Launching a second shift is not only a strategic move for our global competitiveness, but it’s also a meaningful step forward in our commitment to patients around the world.” This commitment is centered around ensuring that timely access to high-quality medicines is not compromised as demand continues to grow.

Enhancing Production and Efficiency

The new second shift will introduce significant advantages, including increased output and faster delivery times. With the pharmaceutical landscape continuously evolving, agility in adapting to various international market demands is vital. This additional shift also provides crucial support to DPG's Research and Development (R&D) division, which is engaged in creating innovative pharmaceutical solutions designed to address the needs of patients globally. By manufacturing these future products in-house, DPG capitalizes on the cutting-edge technologies and processes already in use at its advanced facility based in Blainville, Quebec.

Isabelle Pilon, Executive Director of Operations at DPG, praised the collaborative effort behind this project, emphasizing how the company's culture has played a pivotal role. “From production planning to process optimization, our teams have worked tirelessly to ensure a smooth and sustainable scale-up that remains aligned with our high standards of quality,” she remarked. This operational strategy has incorporated cross-functional insights that reflect the strength of DPG’s workplace culture, setting a foundation for efficient and effective implementation of the second shift.

Commitment to Excellence

Underlining the significance of this expansion is the cohesive work of multiple teams. The dedicated steering committee was instrumental in defining the framework of this initiative, including the project plan, working conditions, and sustainable practices for implementation. Caroline Guerru, Vice President of Human Resources and Communications, described the second shift as a “testament to our commitment to excellence, innovation, and collaboration.” DPG takes pride in fostering a work environment that not only values its employees but also empowers them to make a meaningful impact on healthcare outcomes worldwide.

Looking Ahead

As DPG expands its operations, the company remains firmly dedicated to its mission: improving health outcomes and empowering patients. Continually striving for excellence, DPG aims to cultivate a purpose-oriented and people-centered environment where employees can thrive.

About Duchesnay Pharmaceutical Group

Headquartered in Blainville, Quebec, Duchesnay Pharmaceutical Group encompasses six companies focused on meeting patient needs in Canada, the United States, and beyond. The company specializes in women's health, rare diseases, and orphan generic medications, demonstrating a robust portfolio designed to address a wide range of medical conditions.

DPG’s participation in the Government of Canada's Global Hypergrowth Project exemplifies its unwavering ambition to establish itself as a significant player in the national economy. Winning the 2024 Life Sciences Innovation Award from ADRIQ is a testament not only to its innovative capabilities but also to the supportive workplace environment it nurtures. The company’s ongoing commitment to environmental responsibility and community engagement further underscores its role as a leader in the pharmaceutical industry.

For more insights into Duchesnay Pharmaceutical Group and its initiatives, visit Duchesnay's official website or follow them on LinkedIn.